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ABSTRACT 
 
Coronary heart disease (CHD) is a complex disease caused by the long-term 
progression of atherosclerosis. Lipids, including high-density lipoprotein cholesterol 
(HDL-C), low-density lipoprotein cholesterol (LDL-C), and triglycerides (TG) are well 
established biomarkers for CHD, and are used to predict individual 10-year risk for 
CHD both in the Framingham risk score and in the System for Cardiac Operative Risk 
Evaluation (SCORE) project. Exploring the role and relationship of lipid-related genes 
and lipids in CHD progression can enhance our understanding of CHD etiology. This 
PhD thesis was based on the following studies: 
 
Study I explored the associations between lipid-related genes and myocardial infarction 
incidence. We found that a missense variant in the ABCA1 gene was consistently 
associated with myocardial infarction in two Swedish cohorts, as well as being weakly 
associated with CHD in a large meta-analysis that included 173,975 individuals of 
European descent. 
 
Study II investigated large-scale genetic associations between lipid fractions, including 
data from 188,577 individuals. In this study, there were 157 independent loci associated 
with at least one lipid trait at the genome-wide significant level (P-value < 5 × 10-8), of 
which 62 loci were not previously reported to be associated with lipids in humans. 
 
Study III examined the modifying effect of lifestyles on the genetic variance of CHD 
using twin modeling. We found that a decrease in genetic variance of CHD was 
dependent on increasing body mass index (BMI). This finding indicates that more 
genetic variants or larger effect sizes of genetic variants influence CHD in the lean 
group compared to the obese group. 
 
Study IV investigated the causal relations between lipids and chronic low-degree 
inflammation, measured as high sensitivity C reaction protein (CRP) using a Mendelian 
randomization study design. We found strong observational associations between 
dyslipidemia (decreased HDL-C and/or increased TG) and elevated CRP, but no 
evidence supporting causal relations between dyslipidemia and CRP. The observational 
associations are likely driven by other common causes such as adiposity.    
 
In conclusion, the findings in the current thesis highlight genetic determinants of blood 
lipid levels and their associations with CHD.  Our results suggest a BMI-gene 
interaction effect on CHD. Further, our results suggest that the observational 
associations between dyslipidemia and chronic low-degree inflammation are more 
likely to be driven by other common causes such as adiposity. All these findings shed 
light on the complex mechanisms underlying CHD, particularly those that act through 
lipid metabolism pathways. 
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associated with myocardial infarction in two Swedish cohorts, as well as being weakly 
associated with CHD in a large meta-analysis that included 173,975 individuals of 
European descent. 
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data from 188,577 individuals. In this study, there were 157 independent loci associated 
with at least one lipid trait at the genome-wide significant level (P-value < 5 × 10-8), of 
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using twin modeling. We found that a decrease in genetic variance of CHD was 
dependent on increasing body mass index (BMI). This finding indicates that more 
genetic variants or larger effect sizes of genetic variants influence CHD in the lean 
group compared to the obese group. 
 
Study IV investigated the causal relations between lipids and chronic low-degree 
inflammation, measured as high sensitivity C reaction protein (CRP) using a Mendelian 
randomization study design. We found strong observational associations between 
dyslipidemia (decreased HDL-C and/or increased TG) and elevated CRP, but no 
evidence supporting causal relations between dyslipidemia and CRP. The observational 
associations are likely driven by other common causes such as adiposity.    
 
In conclusion, the findings in the current thesis highlight genetic determinants of blood 
lipid levels and their associations with CHD.  Our results suggest a BMI-gene 
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1 INTRODUCTION 
 
1.1 CORONARY HEART DISEASE 
1.1.1 Current burden and distribution of coronary heart disease 
Coronary heart disease (CHD), also known as coronary artery disease (CAD) or 
ischemic heart disease (IHD), is caused by reduced blood flow in narrowing coronary 
arteries. CHD is a long-term consequence of the atherosclerotic process. 
 
CHD is the leading cause of morbidity and mortality worldwide.1 In 2011, the total 
number of deaths due to CHD was estimated at 7 million.2 The Global Burden of 
Disease Study projections indicate that CHD will continue to be the global leading 
cause of death up to at least the year 2030.3 However, in recent years, the age-
standardized mortality rate for CHD has decreased in many developed countries, while 
it has increased in developing countries. It is estimated that developing countries will 
contribute 71% (7.8 of 11.1 million) of total mortality due to CHD in 2020, compared 
to 56% (3.5 of the 6.2 million) in 1990.4 In addition, non-fatal CHD events contribute 
significantly to overall disability, estimated by disability-adjusted life years (DALYs). 
By 2020, the global burden of CHD is projected to cause 82 million DALYs.4 
Population-specific projections have indicated that the numbers of DALYs are 
expected to increase in India and China.4 By contrast, the number of DALYs is 
expected to decrease in countries with established market economies. The increased 
mortality rates and DALYs in developing countries have been suggested to primarily 
be due to changes in demography, such as urbanization, and lifestyle changes.4 
 
1.1.2 Genetic determinants of coronary heart disease 
Familial aggregation of CHD suggests evidence of a genetic predisposition. Individuals 
with parental cardiovascular disease (CVD) have approximately a 2-fold greater risk of 
CHD,5, 6 while even greater risk is exhibited in those with affected siblings.7 Such 
families represent 72% of early onset CHD cases and 48% of cases at all ages.8 Twin 
studies further elucidate the familiar aggregation of CHD into genetic influences and 
shared environmental influences, such as social economic status and dietary habits. 
Previous twin studies reported 40% heritability of CHD mortality in Swedish 
populations,9 and similar heritability of CHD in other Caucasian European ancestry 
populations.7 In addition, twin studies also suggest a very low shared environmental 
influence on CHD. In agreement with these studies, adoptee investigations show that 
adoptees have a similar risk of CHD mortality as their biological parents, but not as 
their adoptive parents.10 
 
Candidate gene association studies for CHD have focused mainly on variants in known 
pathological pathways, such as hyperlipidemia or inflammation. Although over 5,000 
publications have identified candidate genes implicated in CHD, very few findings 
have been robust, mainly due to inadequate sample sizes, between-study heterogeneity 
and lack of proper replication. Candidate gene studies for CHD have been previously 
comprehensively reviewed elsewhere.11 
 
Over the past 7 years, genome-wide association studies (GWASs) have identified 
genetic variants related to CHD using a hypothesis-free design. Recently, the total 
number of susceptibility loci for CHD has updated to 46, based on joined analyses from 
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the Coronary ARtery DIsease Genome wide Replication and Meta-analysis 
(CARDIoGRAM) plus The Coronary Artery Disease (C4D) genetics consortium 
(CARDIoGRAMplusC4D).12 This study included 34 independent samples with patients 
of European or South Asian descent and comprised 41,513 cases and 65,919 controls. 
Among the leading 46 CHD-related loci, 12 were associated with at least one lipid trait 
reaching GWA significance level, 5 with blood pressure, but none with type 2 diabetes 
(T2D).12 These 46 loci, together with another 104 loci at a 5% false discovery rate, 
explain 10.6% of CHD heritability. Network analysis based on candidate loci using a 
10% false discovery rate mapped the most significant pathways to lipid metabolism and 
inflammation. In addition to the loci found in Europeans, a GWAS in Han Chinese 
subjects revealed four novel loci previously not observed in Europeans,13 two of which 
were reported to be associated with hypertension in Europeans.13 
 
All CHD-related loci based on GWASs are described in detail in their respective 
original studies and a statement from the American Heart Association.12-22 
 
1.1.3 Risk factors for coronary heart disease 
The 10-year individual risk for CHD can be estimated by Framingham risk score23 and 
System for Cardiac Operative Risk Evaluation (SCORE) risk charts24 based on multiple 
traditional risk factors, including age, sex, ethnicity, smoking, blood pressure, blood 
cholesterol, and diabetes.25 In addition, obesity and lifestyle factors, including physical 
activity, harmful use of alcohol and unhealthy diet (e.g., high cholesterol, high saturate 
fatty acids, high salt, or high sugar), are also well established traditional risk factors for 
CHD. Population attributable risk calculations show that traditional risk factors can 
explain 75–85% of CHD occurrence in the United States.25 
 
Widespread concerns over CHD have directed focus towards the identification of novel 
risk factors for this disease. These novel risk factors can enhance our understanding of 
atherosclerosis pathology, providing intervention targets for CHD treatment and 
acquiring more accurate and reliable CHD risk assessments, particularly for the 
intermediate risk group that carry a 10–20% CHD risk.26 Epidemiological studies have 
identified novel blood and urine biomarkers associated with CHD. For example, 
increased circulating inflammatory marker C-reactive protein (CRP) is associated with 
CHD risk.27-30 Furthermore, CRP improves the risk reclassification for intermediate risk 
individuals (10–20% CHD risk).29, 30 However, recent studies suggest that CRP is a 
biomarker rather than a causal risk factor for CHD.31 In addition, circulating lipoprotein 
(a) (Lp[a]), which is a protein that is attached to low-density lipoprotein (LDL) 
particles, is positively associated with CHD in perspective studies32 and it was 
proposed as a causal factor based on genetic studies.33-35 
 
Furthermore, structural and functional changes in subclinical atherosclerosis are 
associated with increased CHD risk, including carotid intima-media thickness (IMT), 
carotid plaques, brachial artery flow-mediated dilation (FMD), and coronary artery 
calcification (CAC) score.36-39 A systematic review reported that carotid IMT, carotid 
plaques, and CAC can also improve risk reclassification of the intermediate risk 
group.40 
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The American College of Cardiology and the American Heart Association jointly 
updated the risk assessment guidelines for atherosclerotic CVD in 2013.41 After 
reviewing publications from 2008 to 2013 for various novel risk factors, this report 
recommends that one or more of the following risk factors can be considered in the 
treatment decision making process when there is no definitive decision based on 
quantitative risk assessment: family history, CRP, CAC score, and ankle-brachial index 
(ABI).41  
 
1.2 LIPIDS AND CORONARY HEART DISEASE 
1.2.1 Lipid metabolism 
The term “blood lipids” mainly refers to the levels of cholesterol and triglycerides (TG) 
in the blood. There are three pathways for maintaining circulating blood lipids levels: 
1) the exogenous pathway for delivering dietary lipids; 2) the endogenous pathway for 
delivering lipids synthesized in the liver; and 3) the reverse cholesterol transport 
pathway for transferring cholesterol in peripheral tissues back to the liver. 
 
1.2.1.1 Exogenous pathway 
In the exogenous pathway, dietary fats and cholesterol are absorbed and packaged 
together with apolipoprotein B-48 (shown as B-48 in Figure 1) to form nascent 
chylomicrons in intestines. Nascent chylomicrons are secreted into the blood and 
become mature chylomicrons by combining with apolipoprotein C-II (C-II in Figure 1) 
and apolipoprotein E (E in Figure 1) donated from high-density lipoprotein (HDL) 
particles. Circulating chylomicrons are hydrolyzed by lipoprotein lipase (LPL), which 
release fatty acids and glycerol into peripheral tissues to be used for energy (e.g., in 
muscle tissue) and storage (e.g., in adipose tissue). Chylomicron remnants are removed 
from the blood within 8–10 hours after food intake, via chylomicron remnant receptors 
expressed in the liver (Figure 1). 
 
1.2.1.2 Endogenous pathway 
In the endogenous pathway, TG and cholesterol esters are synthesized in the liver and 
packaged to form very low-density lipoproteins (VLDLs), which are secreted into the 
blood. Circulating VLDLs release fatty acids and glycerol into peripheral tissues in a 
manner similar to chylomicrons in the exogenous pathway. Next, some of the VLDL 
remnants are removed from the blood via LDL receptors in the liver. The remaining 
VLDL remnant particles become intermediate-density lipoproteins (IDLs), which are 
smaller and denser than VLDLs. The IDL particles can either be taken up in liver by 
LDL receptors or hydrolyzed in the liver by hepatic-triglyceride lipase (HL in Figure 
1) to form LDLs. 
 
LDLs are the main vehicle for circulating cholesterol to peripheral tissues, forming 
LDL cholesterol (LDL-C). Most of the LDL particles are taken up by LDL receptors in 
the liver; the remaining LDLs are removed by way of scavenger pathways at the 
cellular level. As LDL is taken up by receptors, free cholesterol is released and 
accumulates within the cells. LDL receptor activity and LDL uptake regulate plasma 
LDL concentration by several mechanisms, including decreasing the synthesis of 
hydroxy-3-methyglutaryl coenzyme A (HMG-CoA) reductase (which controls the rate 
of cholesterol synthesis), suppressing the synthesis of new LDL receptors in cells, and 
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activating the enzyme acyl-coenzyme A cholesterol acyltransferase, which esterifies 
free cholesterol into cholesterol esters, thereby storing cholesterol in the cell. 
 
1.2.1.3 Reverse cholesterol transport pathway 
HDL particles carry cholesterol from atherosclerotic lesions, which is an important 
process of preventing atherosclerosis, and HDL cholesterol (HDL-C) is therefore 
considered the “good” cholesterol. Nascent HDL is primarily synthesized in the liver 
and intestine, and is composed of phospholipids, apolipoprotein A-1, and very little 
cholesterol. Nascent HDL captures free cholesterol in peripheral tissues, carries it back 
to the liver, and becomes a mature HDL particle by activating lecithin-cholesterol acyl 
transferase (LCAT) and apolipoprotein A-1 (A-1 in Figure 1).  
 
Figure 1. Lipid metabolism and lipoproteins involved in this process (adapted from 
Kwiterovich et al, 2000). 
 
Multiple proteins and enzymes are involved in regulating lipid metabolism and 
maintaining blood lipid levels within a physiological range. Mutations in these 
regulators can disrupt lipid metabolism and cause cholesterol accumulation. Previous 
GWASs for lipid traits reported 95 loci associated with at least one of total cholesterol, 
HDL-C, LDL-C, and TG during fasting status.42 Multiple loci had been observed in the 
aforementioned study, which were nearby/in genes known to be involved in lipid 
regulation, such as APOB, APOE, CEPT, LCAT, LDLR, LPL. The targets of lipid-
lowering drug targets were seen as well, such as HMGCR for statins.42 Of the 95 
reported loci, 59 had not previously been associated with the level of circulating lipids. 
In total, these 95 loci explain 10%–20% of total variance for each lipid fraction, which 
represents 25%–30% of the genetic variance. Genetic studies using larger sample sizes 
are required to reveal more loci associated with lipids and to uncover functional single-
nucleotide polymorphisms (SNPs) in known loci. 
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1.2.2 Utility of lipid measurements in coronary heart disease 
Lipid measurements are essential both for risk prediction in the primary prevention of 
CVD and to identify treatment targets in the primary and secondary prevention of 
CHD. Elevated total cholesterol, LDL-C, and reduced HDL-C levels have all been 
shown to be strong independent risk factors for CHD in numerous epidemiological 
studies.  
 
Statins are the first line of treatment for most people with high cholesterol, and they 
have been shown in multiple research studies to reduce both CHD incidence and 
mortality.43-45 They are HMG-CoA reductase inhibitors that suppress cholesterol 
biosynthesis, and are currently the most commonly prescribed lipid-lowering 
medication. Statins primarily operate by lowering LDL-C levels, but they also cause a 
slight raise in HDL-C and a slight decrease in TG levels.  In recent updates from 
ACC/AHA Blood Cholesterol Guidelines, extended use of statins for both primary and 
secondary prevention of CHD is recommended. In addition, four major patient groups 
that potentially benefit from statins were identified: 1) patients with clinical CVD 
(recommended high-intensity statin therapy); 2) individuals with familiar 
hyperlipidemia who have LDL-C ≥190 mg/dL (4.9 mmol/L); 3) diabetic individuals 
with LDL-C levels between 70 and 189 mg/dL (1.8-4.9 mmol/L) and non-clinical 
CVD; and 4) non-diabetic individuals with a 10-year risk for CVD ≥7.5% and non-
clinical CVD.46 
 
Elevating HDL-C level has been considered a secondary target of lipid modifying 
pharmaceuticals for CHD prevention in the past decade. However, several drugs that 
aimed to elevate HDL-C level subsequently failed to prevent CHD.47 Furthermore, 
recent genetic studies indicate that HDL-C is not a causal factor for CHD.48, 49 Some 
studies have shown that the HDL particle function is a better biomarker for HDL than 
HDL-C. Further studies are required to identify the causal effect of HDL particles on 
CHD. 
 
Although overwhelming evidence already supports the theory that abnormal lipid 
metabolism can affect the atherosclerotic process, much previous research regarding 
lipid metabolism primarily focused on blood total cholesterol, HDL-C, LDL-C, and TG 
levels. More recently, mass spectrometry-based methods that comprehensively annotate 
lipid species (via lipidomics) and other metabolites (via metabolomics) provide a 
powerful platform for identifying novel lipid markers of CHD risk. Furthermore, these 
technique will increase our understanding of lipid metabolic pathways involved in 
atherosclerosis pathogenesis, which will facilitate the development of new treatments.50   
 
1.2.3 Lipids and inflammation 
Both blood lipids and inflammation are important risk factors for CHD. The relations 
between lipids and inflammation have been discussed in recent years. There is some 
evidence that suggests that lipids play a role in inflammation. Previous studies have 
shown that high cholesterol diets, as well as saturated fatty acid consumption, are 
associated with increased CRP levels, which is known as metabolic inflammation.51 In 
addition, transcription factors sensing circulating lipids can regulate the expression of 
genes involved in inflammatory pathways, including peroxisome proliferator-activated 
receptors,52, 53 liver X receptors,54 and farnesoid X receptors.55 On the other hand, some 
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studies suggest that inflammation alters lipid metabolism. For instance, lipid 
metabolism is modified during acute phase inflammation. Chronic inflammatory 
diseases like dermatomyositis,56 rheumatoid arthritis,57 and systemic lupus 
erythematosus58 are often accompanied by reduced HDL-C and elevated TG levels. In 
addition, inflammation has been suggested to decrease toxicity through modifying lipid 
metabolism, which represents a highly conserved response aimed at tissue repair in 
evolution.59 There are also reasons to believe the third explanation, i.e. common causes 
for chronic inflammation and dyslipidemia. Mendelian randomization (MR) study has 
shown body mass index (BMI) causally affect both lipids and CRP.60 
 
1.3 LIFESTYLE INTERVENTION FOR CORONARY HEART DISEASE 
The National Institutes of Health (NIH) in the United States suggests that CHD can be 
prevented through a healthy lifestyle, including the following items: following a 
healthy diet, being physically active, maintaining a healthy weight, quitting smoking, 
and managing stress.55 Lifestyle factors, including smoking, physical inactivity, 
harmful use of alcohol, unhealthy diet, and high BMI are essential risk factors for CHD 
as well as stroke. 
 
Prospective studies consistently show lower CHD mortality in former smokers than in 
current smokers. Furthermore, CHD risk is reduced relatively quickly after smoking 
cessation.61, 62 Patients who quit smoking after initial CHD diagnosis experienced a 
50% reduced risk of CHD occurrence and total mortality,63, 64 even in elderly patients.65 
Studies in both animals and humans have shown that smoking induces endothelium 
injury, which causes increased platelet activation and enhanced thrombus growth and 
propagation.2, 66-68 
 
Physical activity has an independent protective effect on CHD.69-75 When using 
category/quantitative measurements of physical activity, a dose effect of physical 
activity on CHD protection was also reported.75 Any amount of activity for people with 
a sedentary lifestyle is encouraged and additional health benefits are acquired with 
more active exercise. 
 
In a recent systematic review, it was reported that all levels of alcohol consumption 
above 2.5 g per day reduced the risk of incident CHD, but a greater risk of 
cardiovascular mortality and stroke incidence amongst those who consumed more than 
60 g per day was also observed.76 
 
Individuals who were overweight or obese had an increased risk of CHD compared to 
those of healthy bodyweight.77-80 A pooled analysis based on 97 prospective cohorts 
reported that each 5 kg/m2 increase in BMI was associated with a 27% increased hazard 
for CHD.80 Although weight loss is potentially beneficial for CHD prevention, 
medication for lowering weight over the long-term was not successful,81-83 and weight 
loss surgery is only recommended for extremely obese people.84, 85 A recent clinical 
trial reported that physical activity intervention aimed at weight loss did not reduce 
CHD risk in overweight/obese patients with T2D.86 
 
Taking together, lifestyle intervention studies show that CHD is partially preventable. 
There are a few studies have reported single genotype–environment interaction effects 
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on CHD,  i.e., APOE- smoking,87 FTO- physical inactivity,88 ADH1C- alcohol 
consumption89 interaction effects on CHD risk. However, few studies have addressed 
the overall effects of various lifestyle factors in modifying the role of genetic effects on 
CHD. Understanding gene-lifestyle interactions and CHD is critical to provide 
appropriate lifestyle intervention guidelines for specific groups. 
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2 AIMS 
 
The overall aim of this thesis is to explore the role of lipid-related genes in CHD 
incidence. The specific aims include: 
 
I. To investigate associations between lipid-related genetic variants and incident 
myocardial infarction (MI) using a candidate gene study design; 
 
II. To investigate genetic variants associated with lipids using a genome-wide 
association design; 
 
III. To investigate gene-environmental interaction effects on CHD using a twin 
study design; 
 
IV. To investigate causal relationships between different lipid fractions and 
inflammation using a bi-directional MR study design. 
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3 STUDY SAMPLES 
 
3.1 SWEDISH TWIN REGISTRY 
The Swedish Twin Register (STR) is a nationwide twin register in Sweden. At present, 
it contains information on more than 194,000 twins born between 1886 and 2008. Over 
the past 10 years, DNA information was obtained from 45,000 twins, 15,000 of which 
also provided blood serum measurements. Thus, the STR is a powerful resource for 
molecular epidemiological research.90 In the current thesis, we used the oldest cohorts 
of the STR to investigate CHD. Detailed information regarding each cohort within the 
STR is described below. 
 
3.1.1 Cohort I and Cohort II 
Cohort I is a birth cohort including all same-sex twin pairs born between 1886 and 
1925. Several questionnaires were sent to these twins between 1960 and 1970,91 which 
contained questions regarding the following information: twin similarity, marital status, 
urban or rural living, smoking, height and weight, education, dental status, family, 
diseases status, and medication. 
 
Cohort II is a birth cohort including all same-sex twin pairs born between 1926 and 
1958. A mailed questionnaire was sent to those individuals in 1972 to 1973;91 similar 
information to Cohort I was collected, and questions regarding personality were also 
included. Cohort I and II were used in Study III. 
 
3.1.2 GOSH 
GENDER, OCTO-twin, SATSA, HARMONY, collectively known as GOSH, is a 
combination of four STR sub-cohorts. GENDER (Sex differences in health and aging) 
is a study of unlike-sexed twins born during 1906 to 1925.92 Participant information 
was collected using questionnaires, health assessments, cognitive testing, and blood 
sampling in six cycles. OCTO-Twin (Individual differences among the oldest-old) is a 
study of the etiology of individual differences among the oldest-old.93 All 80-year-old 
and older twin pairs who were both alive at study initiation in Sweden were recruited to 
participate. The study was completed with five waves of data collected at 2-year 
intervals. SATSA (Swedish Adoption and Twin Study of Aging) was initiated in 1984 
and included approximately 150 twin pairs reared apart and 150 twin pairs reared 
together.94 The first three waves of the study were conducted at 3-year intervals with 
the fourth in 1999, the fifth in 2002, and the sixth in 2005. HARMONY (the Study of 
Dementia in Swedish Twins) was initiated to evaluate the role of genetic and 
environmental factors on dementia.95 All twins from the STR aged 65 and older were 
invited to participate in a computer-assisted telephone screening interview in 1998, 
from which 1,488 twins not identified in earlier studies updated their clinical diagnoses 
in the HARMONY study. There were a total of 2,618 individuals from GOSH with 
blood samples, which we used in Study I and II. 
 
3.1.3 TwinGene 
Between 2004 and 2008, a total of 12,614 twins from the STR participated in the 
TwinGene project. All individuals answered a mailed health questionnaire. In addition, 
they also underwent a health checkup and gave blood samples in a local healthcare 
facility. More extensive phenotypic information from these individuals can also be 
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obtained from questionnaires implemented in the Screening Across the Lifespan Twin 
Study (SALT). In addition, most same-sex twins in this project were from Cohort II, 
which provides rich phenotypic information obtained during their youth and during 
middle age. TwinGene data was used in Study II and IV. 
 
3.2 ULSAM 
Uppsala Longitudinal Study of Adult Men (ULSAM) is a community-based 
longitudinal study of unrelated individuals.96 All men born between 1920 and 1924 
who were residents of Uppsala County, Sweden were invited to a health examination. 
All men participated in the investigation at 50 years of age, and they have been re-
examined five times to date. Blood samples were collected during re-examination at 
age 71. The ULSAM data was used in Study I, II, and IV. 
 
3.3 PIVUS 
Prospective Investigation of the Vasculature in Uppsala Seniors (PIVUS) is another 
community-based longitudinal study of unrelated individuals.97 A random sample of 
1,016 subjects aged 70 years living in the community of Uppsala, Sweden participated 
in this study between 2001 and 2004. Basic information, blood samples, and 
comprehensive vasculature measurements were recorded at ages 70, 75, and 80. The 
PIVUS data was used in Study II and IV. 
 
3.4 FOLLOW-UP AND CORONARY HEART DISEASE DEFINITION 
3.4.1 National Patient Register 
The Swedish National Patient Register (NPR) is a nationwide register that collects 
information from in-hospital treatments in Sweden, which is maintained by the 
National Board of Health and Welfare. The disease status of participants from all STR 
cohorts and ULSAM can be linked in the NPR via a Swedish personal number. The 
register contains information on the cause of hospitalization with discharge diagnosis 
codes, including the principle cause and several contributing causes. The first CHD 
case was recorded in 1969 and the registry was completed with nationwide coverage in 
1987. Information from the NPR was used to identify the first hospitalization 
information resulting from MI (the outcome in Study I) and resulting from CHD (the 
outcome in Study III). 
 
3.4.2 Cause of Death Register 
The Cause of Death Register (CDR), also kept by the National Board of Health and 
Welfare, includes mandatory reported information from death certificates for all 
deceased individuals in Sweden. It contains data on the principal and contributing 
causes of death, coded according to the International Classification of Diseases (ICD). 
The register was established in 1952, and it contains complete information on causes of 
death since 1961. Information from the CDR was used to identify death resulting from 
MI (the outcome in Study I) and death resulting from CHD (the outcome in Study III). 
 
3.4.3 Coronary heart disease definition 
MI occurrence was defined by the following ICD codes: ICD-7 codes before 1968, 
420.10, 420.17; ICD-8 code from 1968 to 1986, 410; ICD-9 code from 1987 to 1996, 
410; and ICD-10 codes from 1997 to present, I21 and I22. The first occurrence of MI 
was the endpoint in Study I. 
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The occurrence of CHD was defined as occurrence of MI or occurrence of unstable 
angina. ICD codes for CHD are ICD-7 codes before 1968, 420; ICD-8 code from 1968 
to 1986, 410, 411; ICD-9 code from 1987 to 1996, 410, 411B; and ICD-10 codes from 
1997 to present, I20, I21 and I22. In addition, individuals who had undergone surgery 
for percutaneous transluminal coronary angioplasty (PTCA) and coronary artery bypass 
graft (CABG) were considered to be a CHD case. Surgical codes for PTCA and CABG 
considered were 3080, 3127, 3158 before year 1997 and FNG02, FNG05, FNC, FND, 
FNE from year 1997 onward. The first occurrence of CHD was the endpoint in Study 
III. 
 
Only the main diagnoses (i.e., principal cause of hospitalization or underlying cause of 
death) were included in the outcome definition to increase the validity of the outcome 
(positive predictive value of ~95%).98 
 
3.5 BLOOD BIOMARKER MEASUREMENTS 
Serum total cholesterol, HDL-C, and TG were measured in GOSH, TwinGene, PIVUS, 
and ULSAM using standard laboratory techniques. LDL-C was calculated based on 
Friedewald’s formula (LDL-C = total cholesterol – HDL-C – 0.45*TG). Lipid fractions 
were measured after overnight fasting, except for individuals from OCTO-Twin in 
GOSH and 3% of participants in TwinGene. Lipid measures were used as outcomes in 
Study II and Study IV. High sensitivity CRP was measured in TwinGene, PIVUS, and 
ULSAM and used in Study IV. 
 
3.6 GENETIC MARKERS 
3.6.1 GOLD chip 
The GOLDchip was a custom chip designed to identify lipid-related gene regions. All 
candidate genes selected were related to at least one serum HDL-C, LDL-C, or TG trait 
through a literature search based on publications between 2003 and 2008. All known 
SNPs were taken into consideration if they are within or in linkage disequilibrium (LD) 
with potential gene regions based on HapMap2 CEU panel, NCBI Build36. A region 
approximately 20 kb upstream and 10 kb downstream of each examined gene was 
selected using the UCSC Genome Browser. After selection, Illumina scores for all 
markers were calculated; those that did not satisfy the criteria for Illumina probe 
chemistry were then replaced with an SNP in perfect LD (r2 = 1) if available, or other 
tagging SNPs. 
 
GOSH samples were genotyped using GOLDchip, which were used in Study I. 
Genotyping was performed using the Illumina GoldenGate assay system (San Diego, 
CA, USA) on the Illumina BeadStation 500GX at Uppsala University SNP Technology 
Platform. 
 
3.6.2 Metabochip 
Metabochip is a custom chip that prioritizes loci based on previous GWASs for 23 
cardiovascular and metabolic traits.99 SNPs were selected if they were correlated with 
at least one lipid fraction with a P < 0.0005 in the original GWASs. Based on the study 
by Tesclovich et al,42 there were 5,023 independent SNPs for HDL-C, 5,055 SNPs for 
LDL-C, 5,056 SNPs for TG, and 938 SNPs for total cholesterol. In addition, 28,923 
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additional SNPs were selected for fine mapping 65 lipid-related regions. There were 
50,459 and 93,308 SNPs selected for prioritizing and fine mapping for non-lipid traits, 
respectively, based on previous GWASs. 
 
GOSH, PIVUS, and ULSAM samples were genotyped using Metabochip, which were 
used in Study II. Genotyping was performed at Uppsala University SNP Technology 
Platform using the Illumina iSelect Metabochip genotyping array. 
 
 
3.6.3 Genome-wide arrays 
Illumina OmniExpress and Omni2.5M are two genome-wide genotype microarrays 
designed by Illumina.60 TwinGene and PIVUS individuals were genotyped using 
Illumina OmniExpress genotyping array and ULSAM individuals were genotyped 
using Illumina Omni2.5M genotyping array. Imputation for all studies was performed 
after quality control based on haplotypes from both HapMap 2 and 1000 genome 
project using IMPUTE version 2. 
 
Selected SNPs from PIVUS, ULSAM, and TwinGene data based on the HapMap 2 
panel in NCBI Build36 were used in Study IV. Genotyping was performed at 
Wellcome Trust Sanger Institute, Hinxton, UK (PIVUS) and Uppsala University SNP 
Technology Platform (ULSAM and TwinGene). 
 
3.6.4 Quality control for genotype data 
Similar exclusion criteria were implemented for all studies with respect to quality 
control. 
 
All samples with bad genotyping quality were excluded: 1) call rate < 95%; 
heterozygosity > ±3 standard deviation (SD); 3) duplicates; 4) gender discordance; 
5) ethnic outliner based on HapMap2 multi-ethnic panel; 6) relatedness in PIVUS and 
ULSAM (pi-hat > 0.2); 
 
SNPs meeting the following conditions were excluded: 1) all monomorphisms; 2) 
minor allele frequency (MAF) < 0.01; 3) P-value for Hardy-Weinberg equilibrium 
(HWE) < 10-6; 4) missing genotype rate > 0.01 (if MAF < 0.05) or missing genotype 
rate > 0.05 (if MAF > 0.05). In addition, SNPs were also excluded if they exhibited 
large position disagreements, did not map at all in the genome, if they mapped more 
than once in the genome, and if they have bad probe assays. 
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4 STUDY DESIGNS AND METHODS 
 
4.1 STUDY I 
In Study I, we used a candidate gene study design to investigate the association 
between lipid-related genes and MI incidence, as shown in Figure 2. 
 
Figure 2. Candidate gene design for investigating associations between lipid-related 
genes and myocardial infarction incidence. 
 
 
First, we used the population-based cohort GOSH within the STR as the discovery 
sample. In total, 554 SNPs from 41 lipid-related gene regions were selected for 
GOLDchip. A sex-adjusted Cox regression was performed for each SNP-MI incidence 
association. Considering that life-time disease information from NPR and CDR was 
available for most individuals in GOSH, we allowed each individual to enter the study 
at age 18 and followed them until MI onset, death, or the end of 2008. 
 
Second, SNPs that were significantly associated with MI incidence in the discovery 
sample in ULSAM were directly genotyped; a similar Cox regression model was 
performed for SNP-MI incidence. 
 
Third, for SNPs that were consistently associated with MI incidence in both discovery 
and replication samples, we performed a fixed-effect meta-analysis using all studies 
with European ancestry from CARIDoGRAMplusC4D consortium as an in silico 
replication. 
 
4.2 STUDY II 
In Study II, we combined data from genome-wide genotyping arrays and data from 
Metabochip to explore genetic determinations for total cholesterol, HDL-C, LDL-C, 
and TG, as shown in Figure 3. 
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Figure 3. Study design for joint GWAS and Metabochip meta-analysis. 
 
Teslovich et al reported 95 independent loci associated with lipids based on GWASs in 
94,595 individuals from 23 studies.42 The results from that study were used to select 
prioritized SNPs and fine mapping regions for lipids on the Metabochip, as described 
above. 
 
There were 37 studies genotyped using Metabochip, which included 93,982 total 
individuals. In each participating study, individuals were excluded if they did not fast 
overnight ( > 8 hours) or if they were taking lipid-lowering medication. The residuals 
for each lipid fraction were obtained after adjusting for age, square of age and sex, and 
then inverse-normal transformed. SNP-lipid association tests were performed using 
linear regression with additive genetic models and using normalized residuals as the 
dependent variables. The population structure was further adjusted for studies with 
independent participants (i.e. PIVUS and ULSAM), while mixed effect models were 
performed in studies with family-clustered participants (i.e. GOSH). Large-scale 
associations between SNPs and lipids were performed in each participant study using 
statistical package including PLINK (i.e. PIVUS and ULSAM), MERLIN (i.e. GOSH), 
SNPTest, MMAP, EMMAX and GenABEL. A meta-analysis was performed with the 
Stouffer Z-score method using METAL.100 
 
A locus was considered to be a novel independent signal if it reached the genome-wide 
significant level (P-value < 5*10−8) in the combined results and was at least 1 Mb away 
from the nearest, previously lipid-related loci reported. We used only European 
samples for the discovery of new genome-wide significant loci. 
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4.3 STUDY III 
In Study III, we used a moderator twin model101 to investigate the gene-lifestyle 
interaction effects on CHD. 
 
Lifestyle information was obtained from Cohort I and Cohort II within the STR. In 
total, 51,065 same-sex twins from 25,715 twin pairs were eligible for this study. During 
the 40-year follow-up, 7,264 incident CHD events were recorded. 
 
Classic twin modeling relies on the differences in genetic similarity between 
monozygotic (MZ) and dizygotic (DZ) twins.102 Using this information, we 
decomposed the phenotypic variance into additive genetic variance (A), shared 
environmental variance (C), and non-shared environmental variance (E). Because 
shared environmental factors have little influence on CHD,103, 104 we used an AE model 
to study the gene-lifestyle interaction effect on CHD. 
 
In a moderator twin model (Figure 4), we first adjusted for age (βage*age), cohort effect 
(βcohort*cohort), and measure of the moderator (M) in both twins within a twin pair 
(βm1* M1 and βm2* M2) for the risk of CHD (p). Next, the total variance in CHD risk 
was decomposed into A and E. We hypothesized that both A and E could differ 
depending on the moderator (βa*M and βe*M, respectively). If A is significantly 
different depending on the moderator, i.e., βa significantly differs from zero, then we 
conclude that a gene-moderator interaction effect is evident. We investigated the role of 
age and different lifestyle factors (e.g., smoking, alcohol consumption, sedentary 
lifestyle and BMI) as moderators in our primary analyses. The twin modelling was 
performed using the structural equation modeling package Mx 1.703.105 
 
Figure 4. Moderator twin model for investigating moderator effect on genetic influence 
of coronary heart disease. 
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When a gene-lifestyle interaction effect was evident, we further allowed A and E to 
differ depending on age and lifestyle at the same time in order to explore the gene-
lifestyle interaction while removing the age effect. 
 
4.4 STUDY IV 
In Study IV, we used a Mendelian randomization (MR) study design to investigate the 
bi-direction causal relationships between fasting lipids and CRP, as shown in Figure 5. 
 
Fasting lipids and CRP levels, as well as genetic information, were obtained from 
PIVUS, ULSAM, and TwinGene. There were 10,723 individuals eligible for this study 
after excluding individuals who lacked fasting lipid and/or CRP measurements, were 
using lipid-lowering medications, were in acute phase inflammation (CRP > 10 mg/L), 
and those that lacked genetic data or that did not pass sample genotyping quality 
control.  
 
We investigated the associations between lipids and CRP in three steps. In the first step, 
we estimated the effects of lipid fractions on CRP using linear regression models 
adjusted for age and sex. We further adjusted for the following CHD risk factors: 
smoking, BMI, waist-hip ratio, diabetes, and systolic blood pressure (SBP) and use of 
anti-hypertensive medication. To understand which factors explained the observed 
associations, we used exploratory analyses by adding each CHD risk factor one by one 
to the age- and sex-adjusted model. If the effect size changed with more than 10% 
when adding a specific factor, it indicated that the observed association was partly 
confounded by this factor. The same approaches were applied to investigate the 
observational effects of CRP on each lipid fraction. 
 
In the second step, we explored the causal associations between lipids and CRP using a 
MR design, as shown in Figure 5. The causal effects of lipid fractions on CRP were 
estimated using genetic risk scores (GRSs) or single genetic loci related with each lipid 
fraction as instrumental variables (IVs) in a two-stage least squares (2SLS) linear 
regression.106 The causal effects of CRP on lipid fractions were estimated using CRP-
related GRS or the CRP locus as IVs. Genetic variants as IV estimators for lipids were 
selected based on the results from Study II of the current thesis, while for CRP they 
were selected based on results from Dehghan et al.16 STATA 12.1 (StataCorp, College 
Station, TX, USA) package ivreg2 was used for the IV analyses. All results from the 
first and second steps were based on three study samples using fixed-effect meta-
analyses. 
 
In the third step, we applied the approach by Do et al, which addresses causal inference 
using summarized data,49 to test the robustness of our conclusions from IV analyses. In 
this step, we investigated whether the effects of lipid-related SNPs on each lipid 
fraction were correlated with their effects on CRP, after adjusting for their effects on 
other lipid fractions, such as BMI, waist-hip ratio, fasting glucose, and fasting insulin. 
A significant correlation suggests a causal effect of the lipid fraction on CRP. The same 
approach was applied to investigate causal effects of CRP on lipid fractions based on 
correlations between the effects of CRP-related SNPs on CRP and lipids. 
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Figure 5. Bi-direction Mendelian randomization for causal relations between lipids and C-reactive protein. 
 
 
 
The bi-directional Mendelian randomization design exemplified for the association of high-density lipoprotein cholesterol (HDL-C) and C-reactive 
protein (CRP). The same design was also applied for the other lipid fractions. 
 
 
 18 
5 STUDY SUMMARIES 
 
5.1 STUDY I 
The missense variant rs4149313 in the ATP-binding cassette, sub-family A, member 1 
gene (ABCA1) was consistently related to MI incidence in both the discovery study 
GOSH and replication study ULSAM. Each copy of the effect allele of rs4149313 
increased the hazard of MI incidence in GOSH by 36%, while this increase was 40% in 
ULSAM (Figure 6). In the in silico replication, the association between rs4149313 and 
CHD among all studies with European ancestry was of borderline significance (odds 
ratio [OR] = 1.03; 95% confidence interval [CI] 1.00, 1.06), as shown in Figure 7. 
 
Figure 6. Kaplan-Meier survival functions for rs4149313 and survival of myocardial 
infarct in GOSH (a) and ULSAM (b). 
 
Figure 7. Forest plot for independent replication of association between rs4149313 
and coronary artery disease in CARDIoGRAMplusC4D. 
a. GOSH (Discovery) 
HR=1.36 (1.10, 1.67) 
b. ULSAM (Replication) 
HR=1.40 (1.07, 1.83) 
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5.2 STUDY II 
In this study, we uncovered 157 loci related with at least one lipid fraction based on a 
meta-analysis of up to 188,577 individuals (Figure 8). Each locus was separated by at 
least 1 Mb apart and had a low LD (r2 < 0.10). Only the annotated genes for lead SNPs, 
which showed the strongest association with respective lipid traits, were reported. 
 
For 62 of the 157 loci, this was the first time they have been reported to be associated 
with lipids; 24 demonstrated the strongest evidence of association with HDL-C, 15 with 
LDL cholesterol, 15 with total cholesterol, and eight with TG level (Figure 8). The 
effect sizes associated with newly identified loci were generally smaller than loci 
identified in previous GWASs. For the 62 newly identified variants, the proportion of 
trait variance explained in the Framingham offspring ranged from 1.6% (HDL 
cholesterol) to 2.6% (total cholesterol; 2.1% for triglycerides, 2.4% for LDL 
cholesterol). This brings the total trait variation explained by both primary and 
secondary association signals at previously known loci and these 62 new loci to 
~13.8% for HDL-C, ~14.4% for LDL-C, ~11.7% for TG, and ~14.5 % for total 
cholesterol. 
 
Figure 8. Overlap of loci associated with different lipid traits. 
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5.3 STUDY III 
Table 1 presents the modifying effect of age, smoking, sedentary lifestyle, alcohol 
consumption, and BMI on genetic variance and non-shared environmental variance of 
CHD (βa and βe shown in Figure 4 and Table 1). Both increasing age and increasing 
BMI were significantly related to increasing CHD genetic variance, as well as related to 
even larger increasing environmental CHD variance. 
 
Considering that there was a positive correlation between age and BMI, we further 
investigated the genetic variance and non-shared environmental variance of CHD 
dependent on both age and BMI in the same model. We found that after removing the 
age effect, genetic variance of CHD decreased when BMI increased. BMI-moderating 
effect on genetic variance of CHD was significant in men (βa = -0.04 ; 95% CI -0.07, 
0.00; Figure 9), and showed a similar trend in women (βa = -0.06; 95% CI -0.11, 0.02). 
This suggests that genetic factors play a more important role in CHD in lean individuals 
compared to obese individuals. 
 
There was no evidence that smoking, sedentary lifestyle, or alcohol consumption 
modified the genetic variance of CHD. 
 
Figure 9. Genetic and environmental variance of coronary heart disease dependent on 
body mass index after removing the age effect on coronary heart disease variance. 
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Table 1. Moderating effects of various life-style factors on genetic variance and non-shared environmental variance in coronary heart 
disease. 
 
 
Moderating effect on genetic component is βa, and moderating effect on environmental component is βe 
 
 
 
 
 
 
 
 
 Men Women 
 Moderating effect on 
genetic component      
(95% CI) 
Moderating effect on 
environmental component 
(95% CI) 
Moderating effect on 
genetic component 
(95% CI) 
Moderating effect on 
environmental component 
 (95% CI) 
Age  0.31 
(0.27, 0.31) 
0.45 
(0.41, 0.46) 
0.23 
(0.19, 0.24) 
0.45 
(0.37, 0.45) 
Smoking 0.06 
(–0.06, 0.19) 
0.26 
(0.12, 0.40) 
–0.12 
(–0.24, 0.01) 
–0.22 
(–0.32, –0.10) 
Sedentary lifestyle 0.03 
(–0.15, 0.25) 
–0.10 
(–0.29, 0.12) 
0.24 
(–0.01, 0.53) 
0.01 
(–0.24, 0.30) 
Alcohol 
consumption 
–0.15 
(–0.27 –0.01) 
–0.08 
(–0.22, 0.07) 
0.12 
(–0.32, 0.36) 
–0.34 
(–0.55, 0.06) 
BMI 0.07 
(0.03, 0.11) 
0.26 
(0.20, 0.33) 
0.05 
(0.00, 0.09) 
0.33 
(0.24, 0.38) 
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5.4 STUDY IV 
As shown in Figure 10a, HDL-C and CRP was negatively associated after adjusting for age and 
sex (β = -0.22, P-value < 0.001; Figure 10a), and this association was attenuated when additionally 
adjusting for other CHD risk factors (smoking, BMI, waist-hip ratio, diabetes, SBP and anti-
hypertension medication; β = -0.08, P-value < 0.001; Figure 10a). Exploratory analyses suggested 
that the observed association between HDL-C and CRP were partly confounded by adiposity, as 
both BMI and waist-hip ratio attenuated the association 50% and 28%, respectively. Using the 
HDL-C-related GRS as an IV estimator, we did not observe a causal effect of HDL-C on CRP (β = 
-0.15, P-value = 0.32; Figure 10a). Similar results was shown when using a variant from the 
ABCA1 locus as the IV (β = -0.11, P-value = 0.64; Figure 10a), as well as when applying Do et al’s 
method. Taken together, our results found no evidence of a causal effect of HDL-C on CRP. 
  
Figure 10b presents a weak and positive association between LDL-C and CRP when adjusting for 
age and sex (β = 0.04, P-value < 0.001), and the association was not attenuated when additionally 
adjusting for CHD risk factors as described above (β = 0.04, P-value < 0.001). We did not observe 
a causal effect of LDL-C on CRP when using either the LDL-C-related GRS (β = 0.09, P-value = 
0.58) or the APOB locus (β = –0.10, P-value = 0.46) as IVs. Do et al’s method presented the similar 
results. Taken together, our results did not provide evidence for a causal effect of LDL-C on CRP.  
 
Figure 10c shows a strong positive association between TG and CRP when adjusting for age and 
sex (β = 0.20, P-value < 0.001). The association was attenuated when adjusting for CHD risk 
factors (β = 0.09, P-value < 0.001), which was mainly due to confounding effects of BMI and 
waist-hip ratio (reduced the association between TG and CRP with 47% and 31%, respectively). 
We did not observed a causal effect of TG on CRP in the IV analyses using either the AKR1C4 
locus (β = 0.20, P-value = 0.62) or the LPL locus (β = 0.01, P-value = 0.94) as IVs. Do et al’s 
method produced similar results. Taken together, our results did not provide evidence for a causal 
effect of TG on CRP. 
 
As shown in Figure 11, the observational effects of CRP on HDL-C, LDL-C, and TG were similar 
to the observational effects of HDL-C, LDL-C, and TG on CRP when adjusting for age and sex and 
when further adjusting for CHD risk factors. Exploratory analyses consistently suggested that the 
associations between CRP and HDL-C/TG were mainly confounded by BMI and waist-hip ratio. 
Using the CRP-related GRS or the CRP locus as IVs, we did not observe any causal effect of CRP 
on HDL-C (β = –0.10, P-value = 0.05; β = 0.05, P-value = 0.46, respectively), LDL-C (β = –0.09, 
P-value = 0.08; β = 0.02, P-value = 0.76, respectively), or TG (β = 0.08, P-value = 0.10; β = 0.13, 
P-value = 0.06, respectively). Do et al’s method also suggested no causal effects of CRP on lipids. 
Taken together, our results did not provide evidence for causal effects of CRP on HDL-C, LDL-C, 
or TG. 
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Figure 10. The observational and causal effects of HDL-C (a), LDL-C (b) and TG(c) on CRP. 
 
IV refers to instrumental variable; GRS refers to genetic risk score; ES (95% CI) refers beta 
coefficient with 95% confidence interval; and P refers to P-value.
 
a. 
b. 
c. 
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Figure 11. The observational and causal effects of CRP on HDL-C (a), LDL-C (b) and TG(c). 
 
 
IV refers to instrumental variable; GRS refers to genetic risk score; and ES (95% CI) refers beta 
coefficient with 95% confidence interval; and P refers to P-value.  
a. 
b. 
c. 
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6 DISCUSSION 
 
6.1 FINDINGS AND IMPLICATIONS 
6.1.1 ABCA1 gene and incident MI 
In study I, we investigated associations between SNPs in 41 lipid-related regions and 
MI incidence using a candidate gene approach. We found one missense SNP 
(rs4149313) in the ABCA1 gene that was consistently associated with MI incidence in 
two Swedish cohorts. Furthermore, the association between rs4149313 and CHD was 
borderline significant in a meta-analysis including 173,975 individuals of European 
ancestry. Our results are suggestive of a weak association between this variant and the 
development of atherosclerosis and MI. 
 
The ABCA1 gene encodes a cellular transporter that mediates phospholipids and 
cholesterol transport from inside cells into the blood to from nascent HDL. Certain 
mutations in ABCA1 lead to Tangier disease, which is characterized by a severe 
reduction in HDL.107 rs4149313 is a missense SNP in exon 18 of ABCA1, which 
encodes the amino acid substitution isoleucine to methionine (I883M). This amino acid 
substitution is located at the N-terminal of the first ATP-binding motif. The functional 
prediction of this amino acid substitution is controversial. It was reported to be benign 
by Polymorphism Phenotype 2 (PolyPhen2), while, conversely, it was indicated to be 
functional in PANTHER. However, in vitro experiments demonstrate that cholesterol 
efflux in HEK-293 cells transfected with the rs4149313 variant significantly differed 
from wild-type cells,108 which supports the biological functionality of this variant. In 
addition, this variant is conserved in different species, including zebra fish, western 
clawed frogs, chickens, common turkey, mice, rats, guinea pigs, dogs, bovines, and 
lowland gorillas. The conservation of this variant also indicates its importance, as well 
as offers opportunities for functional studies in different model animals. 
 
6.1.2 Genetic determinants of lipid metabolism 
In Study II, we reported 62 independent novel loci associated with blood lipids. 
Combining this data with previous findings,42 a total of 157 loci have been associated 
with blood lipid levels to date. Through literature review and pathway analyses, there is 
evidence supporting 38 new loci in LD with genes that functionally regulate blood lipid 
levels. 
 
Functional studies are required to identify causal variants as well as to understand the 
molecular mechanisms of relevant genes. For example, we found variants near the G 
protein-coupled receptor 146 gene (GPR146) that were associated with total 
cholesterol. Knockout of Gpr146 in mice modifies blood cholesterol levels suggesting 
that GPR146 is a potential target for hyperlipidemia medication. For the 62 newly 
identified loci, there are a total of 240 genes within 100 kb of each locus. These genes 
provide attractive, albeit challenging due to the extensive work needed to explore the 
large number of genes, candidates for future functional studies. 
 
When comparing lipid-related loci with GWASs for other metabolic and cardiovascular 
traits, many loci were also associated with CHD, BMI, SBP, diastolic blood pressure 
(DBP) and T2D. Furthermore, the effects of SNPs on LDL-C and TG, but not HDL-C, 
were highly correlated with the effect of the same SNPs on CHD, which indicates 
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causal effects of LDL-C and TG, but not HDL-C, on CHD. More detailed analyses 
addressing the causal effects of lipids on CHD based on the results of the current study 
were published in a companion article by Do et al.49   
 
6.1.3 BMI-gene interaction effect on CHD 
In Study III, we found that after removing the age effect, genetic variance of CHD 
decreases when BMI increases. This indicates that genetic factors predisposing to CHD 
play a more important role in lean individuals compared to obese individuals. Genetic 
variance of CHD change dependent on BMI can be explained via two possible 
underlying mechanisms: 1) additional genes may influence CHD variance in those with 
a low BMI; and 2) the magnitude of the effect of some CHD-related genes may differ 
according to BMI level. 
 
Several studies investigating gene-environment effects on metabolic traits support the 
aforementioned second mechanism. For instance, Perry et al reported that 29 out of 36 
known T2D related loci had a larger effect size on T2D in the lean group compared to 
obese group.109 In addition, Lamina et al reported that a GRS associated with increased 
HDL-C had a smaller effect in the obese group compared to the lean group.110 Together 
with our results, this suggests higher expression of HDL-, T2D-, or CHD-related genes 
in lean individuals compared to obese individuals. A GWAS for CHD stratified by 
BMI with adequate study power should be performed to confirm this hypothesis. Based 
on the results of our study, such a GWAS would be especially beneficial in the normal-
weight population as these susceptibility variants may be masked in GWASs that 
include individuals with higher BMIs. 
 
6.1.4 Causal relationships between blood lipids and CRP 
In Study IV, we investigated causal relationships between fasting blood lipids and CRP 
in 10,732 individuals from three Swedish cohorts. We did not find robust evidence for 
causal relationships between CRP and any of the lipid fractions. 
 
In line with our results, randomized trials for cholesteryl ester transfer protein (CETP) 
inhibitors, which target and elevate HDL-C, have achieved their primary aim but have 
not been shown to reduce CRP level or CHD risk.47, 111 Furthermore, intervention trials 
with statin therapy have shown that reduced CRP levels are independent of changes in 
LDL-C levels.112 Taking together, this evidence suggests that there are no causal effects 
of HDL-C or LDL-C on CRP. Currently, there are no intervention trials that primarily 
target lowering blood TG levels, and more studies are required to explore the causal 
effect of TG on CRP. Furthermore, intervention trials using monoclonal antibodies 
against IL-6R have been shown to reduce CRP while moderately elevating HDL-C, 
LDL-C, and TG in rheumatoid arthritis patients.113, 114 One possible interpretation of 
this result is that low-grade inflammation can lead to changes in both CRP and lipid 
fractions, and that the effects on lipid levels are not mediated by CRP, but by 
inflammatory molecules higher up the inflammation cascade. This hypothesis requires 
further investigation using other biomarkers than CRP.  
 
The observational associations between CRP and HDL-C and between CRP and TG 
were attenuated over 50% when adjusting for CHD risk factors, particularly BMI and 
waist-hip ratio, which suggests that adiposity confounds the relation of CRP and 
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dyslipidemia. This result is in line with a recent large MR study which reported that 
BMI is a causal factor for both CRP and dyslipidemia.60 
 
In the post-hoc power calculation for IV analyses, the statistical power for using GRSs 
as IV estimators to investigate causal relations between lipids and CRP were limited, 
especially when investigating causal effects of lipids on CRP, which is the main 
limitation for the current study. Therefore, we applied Do et al’s method, which is less 
sensitive to pleiotropy and provides better power; this method produced results that 
were consistent with our main analyses. In addition, we acknowledge that low-grade 
inflammation can be a causal factor for regulating lipid fractions and that its effect on 
lipids is mediated by inflammatory molecules higher up in the inflammation cascade 
instead of by CRP.  
 
6.2 METHODOLOGICAL CONSIDERATIONS 
6.2.1 Left truncation when using genetic data in survival models 
In Sweden, all medical care is publically funded and available to all citizens, and all in-
patient care, medication and death information is registered in national registries. 
Therefore, we were able to identify the time at the first onset of CHD for those who 
participated in each cohort before or after answering the questionnaire and when they 
gave blood samples. However, we were not able to include those who had fatal CHD 
before the cohort was initiated.  
 
In Study I, we investigated the first MI incident, including cases that had yet to 
participate in GOSH or ULSAM. As DNA sequence is stable over the course of one’s 
life, this approach increased the power of the study and avoided recall bias from disease 
self-reporting. However, with this approach, individuals experiencing fatal MI before 
baseline measurements could be obtained did not enter our study. The potential survival 
bias introduced by such early onset fatal cases could potentially decrease the effect size 
of our findings, and subsequently cause us to accept the null hypothesis. However, 
because MI is a disease that develops over time, occurs repeatedly, and mainly affects 
the elderly, we consider using age 18 as the entry age as an appropriate method for 
dealing with our data to maximize statistical power. In additional sensitivity analyses, 
the association of rs4149313 with incident MI was weaker when using blood draw as 
the time of study entry. This could be due to a potential survival bias caused by those 
whose first MI incidence occurred before 1987, or due to decreased power by losing 
37% of the cases compared to our main analysis. 
 
6.2.2 Twin modeling addressing gene-environment interaction 
The moderate twin model for gene-environment interaction was first developed by 
Purcell et al.101 Using this model, the authors explored how the variance components 
(e.g., genetic variance, shared environmental variance, and non-shared environmental 
variance) of a continuous trait can vary depending on a measured moderator. A binary 
trait like CHD cannot be measured using this method directly as the total variance of 
CHD cannot be estimated using a specific scale. Medland et al modified the method for 
binary traits. Using this modified method, they constrained the total variance of the 
outcome to be one at a certain value of a moderator, and allowed variance components 
to change dependent on the moderator. 115 Furthermore, in their simulation, the 
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narrowest confidence interval for heritability could be obtained if total variance was 
constrained to one when the measured moderator equaled its mean level.115 
 
Purcell et al pointed out that in twin modeling, gene-environment interaction effects 
could be flagged by gene-environment correlations, which refers to the same genes 
regulating both the moderator and phenotype investigated.101 In Study III of the current 
thesis, we removed the CHD variation explained by the moderator via adjusting for the 
measure of moderator for the risk of CHD. Using the method, the “false positive” gene-
environment interaction effects due to gene-environment correlation was excluded. In 
addition, van der Sluis et al reported that a cross twin correlation between phenotype in 
twin 1 and moderator in twin 2 could also cause false positive results using Purcell et 
al’s method116. Therefore, in Study III, we followed Medland’s Mx script of moderator 
twin model for binary traits115 and additionally added the measure of moderator for 
both twins in a pair to adjust CHD risk. 
 
6.2.3 Causal inference using Mendelian randomization 
Identifying causal relationships is always an intriguing topic in medical research. It is 
very difficult to explore causal effects using observational epidemiological research due 
to unmeasured confounders and reverse causality. Randomized controlled trials (RCTs) 
randomize the study subjects before intervention to avoid confounders of the 
intervention effect on outcome and different types of biases; hence, RCT is the gold 
standard to study causal effects. However, there are several disadvantages in RCT 
design, such as high cost, being time consuming, and not always being generalizable or 
ethical. 
 
MR design is based on principles of Mendelian inheritance: genetic polymorphisms 
segregate during gamete formation and are randomly assorted at fertilization. This 
process conducts a natural randomization; that is, all covariates between individuals 
with different polymorphisms can theoretically be balanced.117 Therefore, if certain 
measured genetic polymorphisms directly affect exposure (e.g., CRP gene effect on 
serum CRP levels in Study IV), then the non-confounded association between the 
exposure and outcome can be evaluated using an IV analysis approach.106 Genetic 
variants used as IV estimators need to: 1) be associated with the exposure; 2) not be 
associated with confounders for the exposure-outcome association; and 3) be 
independent of the outcome conditioned on the exposure and confounders.118  
 
With individual-level data, the causal effect of the exposure on the outcome can be 
quantified as the ratio of the effect of each allele change of the IV on outcome divided 
by effect of the IV on exposure.106, 119 Genetic variants can usually only explain a small 
proportion of the phenotypic variation, as was the case in Study I and Study II in the 
current thesis. Therefore, to obtain adequate statistical power, large sample sizes are 
required to study causal associations.120 Using GRS can partially boost statistical 
power, as including multiple genetic variants explains a larger proportion of phenotypic 
variance.121, 122 However, large study samples are still essential, especially when effects 
in observational and causal associations between exposure and outcome are not large, 
as shown in Study IV of the current thesis.123  
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Meta-analyses for GWASs in large consortia have reported regression coefficients 
summarizing the GWA with various traits based on large sample sizes, like Study II in 
the current thesis. They are a powerful source for MR investigations, and an alternative 
to individual-level data. Statistical methods have been developed to calculate causal 
estimates based on summarized data. For instance, simulation data shows causal 
estimates are similar using GRSs based on summarized data to using individual-level 
data if the sample size is the same.124 Furthermore, Do et al reports that the effects of 
lipid-related SNPs on TG correlate with their effects on CHD even after adjusting for 
their effects on HDL-C and LDL-C, which indicates a causal effect of TG on CHD.49 
Using the method described by Do et al, the effects of SNPs on both lipid fractions and 
CHD are accurately estimated based on meta-analyses of GWASs. Moreover, potential 
pleiotropic effects of TG-related SNPs on HDL-C and LDL-C are corrected for by 
adjusting for SNP effects on these lipid fractions. Therefore, we applied Do et al’s 
method in Study IV to test the robustness of our conclusions from IV analyses. 
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7 CONCLUSIONS 
 
Study I reported associations between lipid-related SNPs and incident MI in two 
community-based longitudinal studies with in silico replication in a large meta-analysis 
of GWASs. We consistently detected a weak association between rs4149313 and the 
development of atherosclerosis and MI across studies. rs4149313 is one of the few 
amino acid change variants in the ABCA1 gene known to be associated with reduced 
cholesterol efflux.  
 
Study II annotated 157 independent loci associated with at least one lipid fraction, 
including total cholesterol, HDL-C, LDL-C and TG at the GWA significance level. 
Moreover, we identified 62 novel loci that have not previously been reported to be 
associated with lipid levels in humans.  
 
Study III showed that differences in the genetic component of CHD are a function of 
BMI after correcting for the effect of age. Our results suggest that genetic factors may 
play a more prominent role in disease development in the absence of obesity. 
 
Study IV showed strong observational correlations between dyslipidemia and CRP. 
However, no evidence supported causal effects of any one lipid fraction on CRP, or 
supports causal effects of CRP on lipids. Our results might be limited due to 
insufficient statistical power of the present study or they may indicate that the 
relationship between blood lipid levels and CRP are driven by other common causes, 
such as adiposity. 
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8 FUTURE PERSPECTIVES 
 
8.1 MISSING HERITABILITY 
GWASs are initiated to identify the genetic effect of common variants on common 
diseases.125, 126 Although these studies have provided valuable insights into the genetics 
of CHD and its risk factors, all of these findings taken together explain a relatively 
small proportion of heritability of CHD and other complex traits. This has led to much 
discussion about the “missing heritability” in CHD, as well as other traits. Although 
several hypotheses as to why this heritability remains “missing” have been proposed, 
no single answer has yet been agreed upon. 
 
8.1.1 More common SNPs with very modest effects 
Population genetic theory states that decreased reproductive fitness reduces frequency 
of or entirely erases high-risk genotypes in the population. This theory suggests that 
genetic influence on common diseases should be largely composed of many common 
variants with small to modest effects.127 The effect sizes of SNPs found in GWASs 
nearly fit Poisson distribution, i.e. very few SNPs have a large effect size.128 
Furthermore, when increasing sample sizes, more common variants with even smaller 
effect sizes can be found. For example, we found 62 novel loci in Study II of the 
current thesis based on data from 188,577 individuals, which generally have smaller 
effects than the 95 loci reported in a previous GWAS based on 94,595 individuals.42 
Even larger meta-analyses of GWASs are likely to identify additional common variants 
with modest effects. Further, the incomplete tagging of causal variants by currently 
known lead variants within loci is another common explanation to the missing 
heritability.129 That said, arguments against common variants explaining the whole 
missing heritability have also been raised. Park et al estimated the expected number of 
genetic loci that should be possible to find in GWASs with adequate power.128 Their 
results suggested that even though more common variants with modest effect sizes in 
future GWASs will be uncovered as the sample size increases, these variants together 
will explain a relative small proportion of missing heritability.128    
 
8.1.2 Rare variants 
Since long-term evolutionary selection minimizes individuals at the extremes of traits 
affecting fitness, high-risk genotypes with large effects are rare (usually MAF < 1%). 
McCarthy et al suggested that risk allele frequencies of genetic variants are negatively 
correlated with their effect size.130 Mendelian diseases, which are caused by mutations 
in a single gene, are extreme examples of the rare variant model. Rare variants cannot 
be captured using standard GWAS chips due to insufficient density of genotyping 
arrays. Furthermore, structural variants, including copy number variants (CNV; i.e., 
insertions and deletions) as well as copy neutral variants (i.e., inversions and 
translocations) although rare, can contribute to the “missing heritability”. For example, 
several rare CNV have been reported to be associated with psychological diseases. 131-
133  
 
Fine-mapping approaches can be applied to identify rare variants. Targeted re-
sequencing, exome sequencing or whole-genome sequencing with adequate sample 
sizes is an ideal way for fine-mapping studies.134 Custom-designed genotype arrays, 
such as the Metabochip used in Study II, enrich genotypes in regions involving SNPs 
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associated with cardiovascular and metabolic traits in previous GWASs, which is an 
alternative platform for fine-mapping studies. In addition, imputation based on known 
haplotype information from the 1000 Human Genome Project (1000G) can fill in 
missing genotype data between tag SNPs from GWA genotyping arrays.135  Such 
1000G-imputed data can also be used in fine-mapping studies without de novo 
sequencing. All these fine-mapping designs will be useful to identify rare variants, but 
adequate sample sizes are needed. 
 
8.1.3 Interaction effects  
Heritability estimates based on twin modeling are known to be narrow-sense 
heritability. This method decomposes phenotypic variance into ACE components, 
described in Study III of the current thesis. As narrow-sense heritability refers to the 
proportion of the A component in total phenotypic variance, this method assumes that 
there is no interaction effect between the different components. Therefore, it is possible 
that interaction effects can mask heritability estimates. Previous twin study reports that 
gene-gene interactions primarily modelling into genetic variance can contribute to the 
missing heritability. In addition, if there is a gene-environment interaction, an A-C 
interaction will be modelled into A, while an A-E interaction will be modelled into E. 
For example, in Study III of the current thesis, we found CHD heritability to be higher 
in the lean group compared to the obese group. Further gene-gene interaction and gene-
environment interaction studies with adequate sample size will explain part of the 
missing heritability. 
 
Taken together, it is likely that there is more than one explanation to the missing 
heritability. The missing heritability reflects the complexity of genetic architecture. 
Future studies using different design will complete the missing pieces with regards to 
understanding heritability. 
 
8.2 FROM ASSOCIATION TO FUNCTION IN THE POST-GWAS ERA 
GWASs for metabolic and cardiovascular traits are fruitful and have highlighted 
multiple loci associated with CHD and its risk factors. A key question in the next step 
is to identify the causal variants and to understand their function.  
 
8.2.1 Fine-mapping of known loci 
Although genetic variants identified in GWASs may not be the causal variants, they 
may be in LD with casual variants in the nearby region. Fine-mapping studies can 
identify a complete catalog of all genetic variants in the GWAS loci, which is a good 
starting point for identifying causal variants.136  
 
8.2.2 Functional annotation  
Multiple studies have reported that variants revealed from GWASs are enriched in 
genetic regions influencing gene expression.137, 138 Integrating intermediate functional 
phenotypes such as transcriptomics, proteomics and metabolomics with classic genetic 
analysis can further address the functional consequences of GWAS variants.   
 
Multiple computational approaches have been developed to assign potential function to 
SNPs based on publically available data. For the SNPs in the coding regions, there are 
tools to predict their possible effects on proteins. Such tools include PolyPhen2 and 
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PANTHER, which have been used in Study I and II. SNPs in the non-coding regions 
may affect gene expression at transcriptional, post-transcriptional and post-translational 
level. There is a range of computational tools that have been developed to assign 
potential function of non-coding SNPs, and these have been previously reviewed.136 In 
addition, pathway analyses link the top loci in the same biological pathway on a trait 
from GWAS findings.139 
 
8.2.3 Experimental models to understand gene function 
Once candidate causal genes for diseases have been identified based on approaches 
described above, in vitro and in vivo experiments can be applied to validate these genes 
and to understand their underlying biological mechanisms. In vitro studies based on 
clinical samples are good for translating the biological mechanisms of candidate genes 
in humans. However, it can prove difficult to obtain access to clinical samples with 
relevant genetic variants to culture and manipulate primary cells. Established cell lines 
then provide a good alternative to overcoming these difficulties, but may lead to 
identifying false functional effects of candidate genes due to cellular genomic 
instability and karyotypic abnormalities.136 In vivo studies in animal models, e.g., mice 
and zebrafish, provide opportunities to monitor novel candidate gene function involved 
in disease development. For example, the functional validation of GALNT2, PPP1R3B, 
TTC39B and SORT1, which are lipid-related loci highlighted from GWASs, have been 
performed in mouse models, and other investigations are ongoing.42, 140 
 
Furthermore, several recently developed tools enable genomic modification at single 
points via engineered nucleases, e.g., zinc finger nucleases141 and transcription-
activator-like effector nucleases.142 In addition, the engineered genomic modifying 
system clustered regularly interspaced short palindromic repeats (CRISPR) can target 
multiple independent loci and investigate joint effects of them.143 These methods will 
largely enhance functional research in the post-GWAS era.  
 
GWASs have been criticized for lacking clinical utility due to small effects of genetic 
variants on phenotypes. Lipid-lowering drugs statins target HMGCR, which is a gene 
within a locus associated with LDL-C with small effect size in GWAS. This is a good 
example that the drug efficacy is not necessarily related with effect size of the single 
variant in a GWAS. GWAS-derived functional studies will disentangle the complex 
biological mechanisms of disease and develop suitable treatment strategy. 
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